Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs

This study evaluated the effects of semaglutide on 27 obese PCOS patients unresponsive to lifestyle changes. After three months of weekly 0.5 mg subcutaneous semaglutide treatment, patients experienced an average weight loss of 7.6 kg and a BMI reduction of 3.1, with 80% achieving at least a 5% weight reduction. The treatment also improved insulin resistance and normalized fasting blood glucose in 80% of patients with impaired fasting glucose. For those who continued treatment for six months, the average weight loss increased to 11.5 kg, and BMI decreased from 34.4 to 29.4, with 80% of responsive patients experiencing normalized menstrual cycles. The study concluded that low-dose semaglutide effectively reduces body weight and improves metabolic and reproductive outcomes in obese PCOS patients with minimal side effects.